Shanghai Shen Lian Biomedical shareholders approve board restructuring, abolish supervisory board

Shanghai Shen Lian Biomedical Corporation announced the resolutions of its second extraordinary general meeting of shareholders for 2025, held on September 25, 2025. The meeting saw 87 shareholders and proxies attend, representing 227,953,983 voting shares, or 55.9771% of the company's total voting rights. All proposed resolutions were approved without rejection.

A key resolution passed was the "Proposal on abolishing the supervisory board, amending the 'Articles of Association' and its attachments, and handling industrial and commercial change registration." This resolution received 227,606,334 votes in favor (99.8474%), with 305,149 votes against (0.1338%) and 42,500 abstentions (0.0188%). This decision, classified as a special resolution, garnered over two-thirds of the effective voting rights held by attending shareholders and proxies.

Additionally, the "Proposal on revising and formulating other standardized operational systems" was approved with 227,648,834 votes in favor (99.8661%). The company's board of directors confirmed that the meeting procedures complied with legal requirements and the company's articles of association. Guohao Law Firm (Shanghai) attested to the legality and validity of the meeting's convening, attendance, and voting process.